C4 Therapeutics, Inc. (NASDAQ: CCCC) reported Q1 EPS of ($0.20), $0.05 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $6.15 million versus the consensus estimate of $4.8 million.

For earnings history and earnings-related data on C4 Therapeutics, Inc. (CCCC) click here.